Literature DB >> 17554404

Breast cancer clinical and translational research: analogies and implications for prostate cancer.

Lea Baer1, Silvia C Formenti.   

Abstract

Breast and prostate cancer, respectively, are the most common cancers in women and in men in the United States. The management of locally advanced prostate cancer involves a multidisciplinary approach, bearing similarity to the therapeutic approach to breast cancer. Better understanding of the molecular biology of these cancers and the identification of the role played by the cancer stem cells and the tumor microenvironment may translate into better clinical decision making regarding risk classification and treatment allocation. A systematic assessment is presented of the many parallel evolutions in defining and treating high-risk breast cancer as they pertain to prostate cancer.

Entities:  

Year:  2007        PMID: 17554404      PMCID: PMC1887816     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  106 in total

1.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

2.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

Authors:  M W Kattan; J A Eastham; A M Stapleton; T M Wheeler; P T Scardino
Journal:  J Natl Cancer Inst       Date:  1998-05-20       Impact factor: 13.506

3.  Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.

Authors:  Joseph Ragaz; Ivo A Olivotto; John J Spinelli; Norman Phillips; Stewart M Jackson; Kenneth S Wilson; Margaret A Knowling; Christopher M L Coppin; Lorna Weir; Karen Gelmon; Nhu Le; Ralph Durand; Andrew J Coldman; Mohamed Manji
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

4.  Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.

Authors:  William U Shipley; Michelle Desilvio; Michael V Pilepich; Mack Roach; Harvey B Wolkov; William T Sause; Philip Rubin; Colleen A Lawton
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-19       Impact factor: 7.038

5.  Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.

Authors:  Phillip G Febbo; Jerome P Richie; Daniel J George; Massimo Loda; Judith Manola; Sridhar Shankar; Agnieska Szot Barnes; Clare Tempany; William Catalona; Philip W Kantoff; William K Oh
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

6.  Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.

Authors:  Matthew M Poggi; David N Danforth; Linda C Sciuto; Sharon L Smith; Seth M Steinberg; David J Liewehr; Cynthia Menard; Marc E Lippman; Allen S Lichter; Rosemary M Altemus
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

7.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer.

Authors:  Jacques Lapointe; Chunde Li; John P Higgins; Matt van de Rijn; Eric Bair; Kelli Montgomery; Michelle Ferrari; Lars Egevad; Walter Rayford; Ulf Bergerheim; Peter Ekman; Angelo M DeMarzo; Robert Tibshirani; David Botstein; Patrick O Brown; James D Brooks; Jonathan R Pollack
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-07       Impact factor: 11.205

8.  A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; M Schnall; J E Tomaszewski; A Wein
Journal:  J Urol       Date:  1995-07       Impact factor: 7.450

9.  Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

Authors:  Patrick A Kupelian; Louis Potters; Deepak Khuntia; Jay P Ciezki; Chandana A Reddy; Alwyn M Reuther; Thomas P Carlson; Eric A Klein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-01-01       Impact factor: 7.038

10.  CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation.

Authors:  C Jones; A V Nonni; L Fulford; S Merrett; R Chaggar; V Eusebi; S R Lakhani
Journal:  Br J Cancer       Date:  2001-08-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.